AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction

MLA

Makiko Yasuda, et al. “AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction.” Molecular Therapy: Methods & Clinical Development, vol. 18, no. 607–619, Sept. 2020, pp. 607–19. EBSCOhost, https://doi.org/10.1016/j.omtm.2020.07.002.

APA

Makiko Yasuda, Marshall W. Huston, Silvere Pagant, Lin Gan, Susan St. Martin, Scott Sproul, Daniel Richards, Stephen Ballaron, Khaled Hettini, Annemarie Ledeboer, Lillian Falese, Liching Cao, Yanmei Lu, Michael C. Holmes, Kathleen Meyer, Robert J. Desnick, & Thomas Wechsler. (2020). AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction. Molecular Therapy: Methods & Clinical Development, 18(607–619), 607–619. https://doi.org/10.1016/j.omtm.2020.07.002

Chicago

Makiko Yasuda, Marshall W. Huston, Silvere Pagant, Lin Gan, Susan St. Martin, Scott Sproul, Daniel Richards, et al. 2020. “AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction.” Molecular Therapy: Methods & Clinical Development 18 (607–619): 607–19. doi:10.1016/j.omtm.2020.07.002.